Department of Anesthesia and Intensive Care, Catholic University Hospital "A.Gemelli," Rome, Italy.
Department of Oncology, Catholic University Hospital "A.Gemelli," Rome, Italy.
J Vasc Access. 2024 Mar;25(2):512-518. doi: 10.1177/11297298221122128. Epub 2022 Sep 14.
The use of central venous access devices (CVADs) is of paramount importance to safely deliver antiblastic and support therapies in children with cancer. Though, in pediatric patients, as much as in adults, CVADs are potentially associated with severe complications which may result in unscheduled interruption of therapy, hospitalization, increased morbidity/mortality, and increased cost of care.
We have reviewed retrospectively our experience with CVADs in children with solid tumors and hematologic diseases, with the purpose of verifying if the adoption of well-defined insertion and maintenance bundles might be effective in reducing catheter-related complications, and in particular catheter-related thrombosis.
A total of 227 CVADs were analyzed: 175 peripherally inserted central catheters (PICCs), 50 centrally inserted central catheters (CICCs), and 2 femorally inserted central catheters. All CVADs were non-valved, non-cuffed power injectable polyurethane catheters; 81% were tunneled. Median dwelling time of CVADs was 172 days, for a total number of 39,044 catheter days. A very low incidence of both symptomatic catheter-related thrombosis (0.9%) and catheter-related blood stream infection (0.56 episodes per 1000 catheter days) was found. Unscheduled removal or guidewire replacement because of mechanic complications occurred in 15.7% of CVADs. There was no difference in terms of complications between PICCs and CICCs or between tunneled and non-tunneled catheters.
Our experience with CVADs in oncologic and hematologic children suggests that catheter-related complications may be minimized by the adoption of appropriate insertion and maintenance bundles.
在癌症患儿中,安全地给予抗肿瘤和支持治疗至关重要,这就需要使用中心静脉通路装置(CVAD)。然而,与成人一样,儿科患者的 CVAD 也可能会出现严重并发症,从而导致治疗计划外中断、住院、发病率/死亡率增加以及治疗费用增加。
我们回顾性分析了患有实体瘤和血液系统疾病的儿童患者的 CVAD 应用经验,旨在验证采用明确的插入和维护方案是否能有效降低导管相关并发症,尤其是导管相关血栓形成的风险。
共分析了 227 例 CVAD:175 例经外周置入中心静脉导管(PICC)、50 例中心静脉置管(CICC)和 2 例股静脉置管。所有 CVAD 均为无阀、无袖套、可进行静脉推注的聚亚安酯导管;81%为隧道式。CVAD 的中位留置时间为 172 天,总导管留置时间为 39044 天。导管相关血栓形成(0.9%)和导管相关血流感染(每 1000 天导管发生 0.56 例)的发生率均很低。因机械并发症而计划外拔除或更换导丝的 CVAD 占 15.7%。PICC 和 CICC 之间、隧道式和非隧道式导管之间的并发症发生率无差异。
我们在肿瘤和血液系统儿童患者中使用 CVAD 的经验表明,通过采用适当的插入和维护方案,可最大限度地减少导管相关并发症。